Bristol-Myers Squibb (BMY) Tops Q4 EPS by 14c, Beats on Revenue; Offers FY26 Guidance

Bristol-Myers Squibb (NYSE: BMY) reported Q4 EPS of $1.26, $0.14 better than the analyst estimate of $1.12. Revenue for the quarter came in at $12.5 billion versus the consensus estimate of $12.24 billion.

GUIDANCE:

Bristol-Myers Squibb sees FY2026 EPS of $6.05-$6.35, versus the consensus of $6.02. Bristol-Myers Squibb sees FY2026 revenue of $46-47.5 billion, versus the consensus of $44.2 billion.

For earnings history and earnings-related data on Bristol-Myers Squibb (BMY) click here.

You May Also Be Interested In

• Primoris cuts 2026 outlook on renewables cost overruns, COO exits
• KeyCorp (KEY) files for 158.72M share offering by selling stockholders
• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings